Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis

Sophie N.M. Binks, Michele Veldsman, Adam E. Handel, Saiju Jacob, Paul Maddison, Jan Coebergh, Sophia Michael, Sudarshini Ramanathan, Ava Easton, Mette Scheller Nissen, Maria Isabel Leite, David Okai, Morten Blaabjerg, Masud Husain, Sarosh R. Irani*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.

Original languageEnglish
JournalAnnals of Clinical and Translational Neurology
Volume11
Issue number4
Pages (from-to)1053-1058
ISSN2328-9503
DOIs
Publication statusPublished - Apr 2024

Keywords

  • Autoantibodies
  • Encephalitis
  • Fatigue/etiology
  • Glioma
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Leucine
  • Quality of Life

Fingerprint

Dive into the research topics of 'Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis'. Together they form a unique fingerprint.

Cite this